I wanted to share more information on the new Phase IIa clinical trial funded by our Foundation (MJFF) to test the safety and tolerability of nilotinib in Parkinson’s disease. The trial will investigate the potential of repurposing nilotinib (which many in the patient community know is an FDA-approved treatment for cancer of the white blood cells) in Parkinson’s disease.

You can read more details on the nilotinib trial on our blog and download our guide on what patients and families should know about repurposed therapies.

-Debi